Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High Prices for High Profits?

Aidan Hollis1

  • 1Professor, Department of Economics, University of Calgary, Calgary, AB.

Healthcarepapers
|January 24, 2023
PubMed
Summary
This summary is machine-generated.

Governments face challenges in reimbursing costly rare disease drugs. A fair standard suggests drug prices should not permit profiteering, aiding insurers in determining reimbursement values.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The launch and diffusion of new patented medicines by therapeutic value.

Health affairs scholar·2026
Same author

Divergent Effects of Conflict Exposure on Gendered Attitudes Toward Intimate Partner Violence in Nigeria.

Journal of interpersonal violence·2026
Same author

Armed conflict and child vaccination in Nigeria: the deprioritised preventive care.

BMJ global health·2025
Same author

A Canadian multi-province study of COVID-19 vaccine coverage along area-level social determinants in 2021.

Public health in practice (Oxford, England)·2025
Same author

Applying a diffusion of innovations framework to characterise diffusion groups and more effectively reach late adopters: a cross-sectional study on COVID-19 vaccinations in Canada in late 2021.

BMJ public health·2025
Same author

Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2025

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Rare Diseases

Background:

  • Governments and insurers grapple with high drug costs for rare diseases.
  • Existing cost-effectiveness thresholds are often exceeded by these specialized medications.
  • Lack of clear reimbursement tools hinders fair access for patients.

Purpose of the Study:

  • To address the challenge of determining fair reimbursement for expensive rare disease drugs.
  • To propose a standard for pricing that balances innovation with affordability.
  • To provide guidance for insurers and policymakers.

Main Methods:

  • Analysis of current drug pricing and reimbursement challenges.
  • Review of cost-effectiveness principles in healthcare.

Related Experiment Videos

  • Proposal of a "no profiteering" standard for rare disease drug pricing.

    • Main Results:

    • Rare disease drugs frequently surpass traditional cost-effectiveness benchmarks.
    • Insurers lack adequate frameworks for evaluating reimbursement of these high-cost therapies.
    • A "no profiteering" standard offers a potential solution for fair pricing.

    Conclusions:

    • Establishing a "no profiteering" standard is crucial for equitable drug reimbursement.
    • This standard can guide policymakers and insurers in managing rare disease drug costs.
    • Balancing innovation incentives with patient access remains a key challenge.